Daiichi Sankyo: Q1 FY 2016 Results (Daiichi Sankyo) - Jul 31, 2016 - "Confirmed bioequivalence btw CHS-0214 and etanercept"; "Efficacy: CHS-0214 met the predefined criteria of equivalency in terms of ACR20 and DAS28-CRP"; "Safety and Immunogenicity: CHS-0214 and etanercept exhibited the same profile"
P3 data • Biosimilar
|